Pediatrix Medical Group (MD Quick QuoteMD - Free Report) reported $495.1 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 0.8%. EPS of $0.20 for the same period compares to $0.23 a year ago.

The reported revenue represents a surprise of -0.23% over the Zacks Consensus Estimate of $496.25 million. With the consensus EPS estimate being $0.18, the EPS surprise was +11.11%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Pediatrix Medical Group performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Same-Facility/unit Revenue Growth: 2.3% versus 1.5% estimated by two analysts on average.
• Same-Facility/unit net reimbursement-related factors Growth: 1% versus 1% estimated by two analysts on average.
• Same-Facility/unit patient Volume Growth: 1.3% versus the two-analyst average estimate of 0.1%.

View all Key Company Metrics for Pediatrix Medical Group here>>>

Shares of Pediatrix Medical Group have returned -2.4% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.